References

medsovet

Медицинский Совет

Meditsinskiy sovet = Medical Council

2079-701X2658-5790

REMEDIUM GROUP Ltd.

10.21518/2079-701X-2019-10-146-154

medsovet-3066

Research Article

Онкоурология

Oncourology

Кабазитаксел в лечении кастрационно-резистентного рака: как найти баланс эффективности и безопасности?

Cabazitaxel in the treatment of castration-resistant cancer: hitting the balance of efficacy and safety

https://orcid.org/0000-0001-7754-6624

Волкова

М. И.

Volkova

M. I.

отделения урологии Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Dr. of Sci. (Med.), Lead Researcher, Department of Urology, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

mivolkova6@gmail.com

Гриднева

Я. В.

Gridneva

Ya. V.

к.м.н., научный сотрудник отделения урологии Федерального государственного бюджетного учреждения «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.

Cand. of Sci. (Med.), Researcher, Department of Urology, Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.

gridnevyana@mail.ru

https://orcid.org/0000-0003-0389-564X

Ольшанская

А. С.

Olshanskaya

A. S.

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации; аспирант кафедры онкологии факультета дополнительного профессионального образования Федерального государственного бюджетного образовательного учреждения высшего образования «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства здравоохранения Российской Федерации.

Federal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Moscow Department of Health»; postgraduate student, Chair for Oncology, Faculty of Additional Professional Education, Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation.

anny9191@rambler.ru

Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина» Министерства здравоохранения Российской Федерации.РоссияFederal State Budgetary Institution «Blokhin Russian Cancer Research Center» of the Ministry of Health of the Russian Federation.Russian Federation

2019

24062019

010146154

2019

Волкова М.И., Гриднева Я.В., Ольшанская А.С.

Volkova M.I., Gridneva Y.V., Olshanskaya A.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.med-sovet.pro/jour/article/view/3066

Кабазитаксел – противоопухолевое средство из группы таксанов третьего поколения, продемонстрировавшее эффективность при метастатическом кастрационно-резистентном раке предстательной железы (мКРРПЖ), рефрактерном к доцетакселу. Данная статья посвящена критическому анализу исследований результатов применения кабазитаксела у этой категории пациентов и ключевым аспектам управления токсичностью, связанной с лечением. Также проанализированы возможные сценарии использования кабазитаксела в последовательной терапии мКРРПЖ, включающей ингибиторы андрогенного сигнала и системную радиотерапию.

Cabazitaxel, an antineoplastic agent from the third generation taxan group, has demonstrated efficacy in the treatment of metastatic castration-resistant prostate cancer (mCRPC) refractory to docetaxel. This article is devoted to a critical analysis of studies on the use of cabazitaxel in this category of patients and key aspects of management of treatment-related toxicity. The authors also reviewed possible scenarios for the use of cabazitaxel in the sequential therapy of mCRPC, including androgen receptor signalling inhibitors and systemic radiotherapy.

метастатический кастрационно-резистентный рак предстательной железырефрактерностьдоцетакселкабазитакселтоксичность

metastatic castration-resistant prostate cancerrefractorinessdocetaxelcabazitaxeltoxicity

References1

State of oncological care in Russia in 2018. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU NMIRTS Minzdrava Rossii, 2019. 236 p. (In Russ.).

Halkidou K., Gnanapragasam V.J., Mehta P.B. et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene. 2003;22(16):2466–77.

Grossmann M.E., Huang H., Tindall D.J. Androgen receptor signaling in androgenrefractory prostate cancer. J Natl Cancer Inst. 2001;21;93(22):1687–97.

Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

Berthold D.R., Pond G.R., Soban F., de Wit R., Eisenberger M., Tannock I.F. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–5.

EAU guidelines 2019. Available at: http://uroweb.org/guidelines.

NCCN guidelines version 1.2019 Prostatecancer. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx.

Носов Д. А., Гладков О. А., Королева И. А., Матвеев В. Б., Митин Тимур, Попов А. М. Практические рекомендации по лекарственному лечению рака предстательной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018; 8:458–470. [Nosov D. A., Gladkov O. A., Koroleva I. A., Matveev V. B., Mitin Timur, Popov A. M. Practical guidelines for the drug therapy of prostate cancer. Zlokachestvennye Opukholi: Prakticheskie Rekomendatsii RUSSCO #3s2. 2018; 8:458–470] (In Russ).

Hurwitz M. Chemotherapy in prostate cancer. Curr Oncol Rep. 2015;17(10):44. 10. Locke J.A., Guns E.S., Lubik A.A. et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68:6407–15.

Mita A.C., Denis L.J., Rowinsky E.K., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res. 2009;15(2):723–730.

de Morree E., van Soest R., Aghai A., et al. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation. Prostate. 2016;76(10):927–936.

de Bono J.S., Oudard S., Ozguroglu M., et al; TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration- resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.

Heidenreich A., Scholz H.J., Rogenhofer S., et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol. 2013;63(6):977–982.

Bahl A., Masson S., Malik Z., et al. Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU Int. 2015;116(6):880–887.

Heidenreich A., Bracarda S., Mason M., et al; European Investigators. Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: results of the European compassionate-use programme. Eur J Cancer. 2014;50(6):1090–1099.

Bono J.S.D., Hardy-Bessard A.-C., Kim C.-S., et al. Phase III non-inferiority study of cabazitaxel (C) 20 mg/m2 (C20) versus 25 mg/m2 (C25) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D). J Clin Oncol. 2016;34:5008.

van Soest R.J., de Morree E.S., Kweldam C.F., et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration- resistant prostate cancer. Eur Urol. 2015;67(6):981–985.

de Bono J., Hardy-Bessard A.C., Kim C.S. Phase III non-inferiority study of cabazitaxel 20 mg/ m2 versus cabazitaxel 25 mg/m2 in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (PROSELICA). ASCO Annual Meeting, 2016.

Sella A., Sella T., Peer A., et al. Activity of cabazitaxel after docetaxel and abiraterone acetate therapy in patients with castrationresistant prostate cancer. Clin Genitourin Cancer. 2014;12(6):428–432.

Pezaro C.J., Omlin A.G., Altavilla A., et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and nextgeneration endocrine agents. Eur Urol. 2014;66(3):459–465.

Al Nakouzi N., Le Moulec S., Albiges L., et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol. 2015;68(2):228–235.

Sonpavde G., Bhor M., Hennessy D., et al. Sequencing of cabazitaxel and abiraterone acetate after docetaxel in metastatic castration- resistant prostate cancer: treatment patterns and clinical outcomes in multicenter community-based US oncology practices. Clin Genitourin Cancer. 2015;13(4):309–318.

van Soest R.J., Nieuweboer A.J.M., de Morrée E.S., et al; Dutch Uro-Oncology Study group (DUOS). The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castrationresistant prostate cancer. Eur J Cancer. 2015;51(17):2562–2569.

Antonarakis E.S., Tagawa S.T., Galletti G., et al; TAXYNERGY Investigators. Randomized, noncomparative, phase II trial of early switch from docetaxel to cabazitaxel or vice versa, with integrated biomarker analysis, in men with chemotherapy-naïve, metastatic, castrationresistant prostate cancer. J Clin Oncol. Epub 2017 Jun 20.

Wissing M.D., Coenen J.L., van den Berg P., et al. CAST: a retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel. Int J Cancer. 2015;136(6):E760–E772.

Caffo O., Bria E., Giorgi U.D., et al. Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: final analysis from a multicenter Italian study. J Clin Oncol. 2017;35:Abstract5030.

Delanoy N., Angelergues A., Efstathiou E., et al. Sequencing in metastatic castration-resistant prostate cancer (mCRPC): updated results of the FLAC International Database. J Clin Oncol. 2017;35: Abstract267.

Thibault C., Eymard J.-C., Hardy-Bessard A.-C., et al. Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration- resistant prostate cancer (mCRPC). J Clin Oncol. 2017;35:Abstract5033.

Oudard S., Fizazi K., Sengeløv L., et al. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castrationresistant prostate cancer: a randomized Phase III trial – FIRSTANA. J Clin Oncol. In press 2017.

Fiazi K., Hotte S.J., Saad F., et al. Final overall survival (OS) from the AFFINITY phase 3 trial of custirsen and cabazitaxel/prednisone in men with previously treated metastatic castrate resistant prostate cancer. Ann Oncol. 2016;27(6):1–36.

Louhanepessy R., van Rijssen M., van der Noort V., Bergman A.M. Show More Combination of carboplatin (AUC4) and cabazitaxel (25 mg/m2) in mCRPC patients not or no longer responding to cabazitaxel monotherapy. Journal of Clinical Oncology. 2018 February 20;36(6_suppl):371-371.doi: 10.1200/JCO.2018.36.6_suppl.371.

Massard C., Mateo J., Loriot Y., et al. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Ann Oncol. 2017;28(1):90–95.

Loriot Y., Massard C., Albiges L. et al. Personalizing treatment in patients with castrateresistant prostate cancer: A study of predictive factors for secondary endocrine therapies activity. J Clin Oncol. 2012;30(suppl 5; abstr 213).

Meisel A., von Felten S., Vogt D.R., et al. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): a post-hoc analysis of the TROPIC phase III trial. Eur J Cancer. 2016;56:93–100.

Antonarakis E.S., Lu C., Wang H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371(11):1028–1038.

Antonarakis E.S., Lu C., Luber B., et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration- resistant prostate cancer. JAMA Oncol. 2015;1(5):582–591.

Petrylak D.P., Tangen C.M., Hussain M.H. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-20.

The authors declare that there are no conflicts of interest present.